When we founded the Alzheimer’s Drug Discovery Foundation (ADDF) 25 years ago in honor of our mother, Estée Lauder, there was little hope on the horizon for Alzheimer’s disease. But now, more than ever before, hope is here.
Along with our Co-Founder and Chief Science Officer Dr. Howard Fillit, we have made it our mission, through venture philanthropy, to leave no stone unturned, pushing research boundaries and lending support to ideas that may otherwise have been overlooked. And we are seeing tremendous progress as a result.
Many novel ideas for therapeutics we funded in early stages are progressing through clinical trials, making their way toward patients. We have helped to accelerate the development of new biomarkers to diagnose the disease earlier than ever, and to direct resources toward prevention research to delay the onset and progression of disease.
It is an honor that award-winning scientists like recent Goodes Prize recipients Dr. Rhoda Au, Dr. Miranda Orr, and Dr. Jeff Cummings and entrepreneurs like Bill Gates, Jeff Bezos, the Dolby family, and the Foundation for a Better World continue to work alongside us in advancing our mission to transform the way the world understands Alzheimer’s.
We are confident that these strong partnerships, the loyalty of our donors, and the cutting-edge science we support will eradicate this disease for future generations, finishing the work we started almost three decades ago.
And so, we thank you for your commitment to the search for new and effective Alzheimer’s therapies.
With our gratitude,
